HealthIs Alzheimer’s drug donanemab really a 'turning point' for treatment? The experimental drug donanemab slows the progression of Alzheimer's disease compared with a placebo, but the effect may not be large enough to be noticed by people with the condition or their families News
HealthNew drug donanemab slows cognitive decline in early Alzheimer's The experimental treatment donanemab is now the second antibody drug to slow cognitive decline in people with early stage Alzheimer’s disease, but questions remain about its real-world benefits and safety News